Skip to content

Post-stroke cognitive trajectory according to amyloid deposition

Cognitive decline according to Amyloid Uptake in patients with post-Stroke cognitivE impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005086
Enrollment
196
Registered
2020-06-04
Start date
2020-06-08
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patients who were diagnosed as mild cognitive impairment within 3 months from acute cerebral infarct 2) aged 60-80 3) cognitive impairments were newly developed or aggravated after cerebral infarct

Exclusion criteria

Exclusion criteria: 1) patient who was diagnosed as dementia before the cerebral infarct 2) other neurological, psychiatric, or medical disease that cause cognitive impairment 3) patient taking a cholinesterase inhibitor within 3 months from baseline 4) strategic infarct or large territory infarct involving cortical areas 5) modified Rankin Scale (mRS) >3 6) patients with aphasia 7) blindness, deafness, or severe language impairment that might be impossible for study evaluations 8) severe liver disease or kidney disease that needs dialysis 9) malignancy that was not completely resolved 10) schizophremia or bipolar disorders (DSM-IV Axis I psychiatric disease) 11) mental retardation 12) history of encephalitis 13) head trauma history that caused loss of consciousness>1 hour 14) history of traumatic intracranial hemorrhage, brain tumor, or subarachnoid hemorrhage 15) abnormality in thyroid function tests 16) vitamin B12 or folate deficiency 17) neurosyphilis 18) history of metabolic encephalopathy

Design outcomes

Primary

MeasureTime frame
Mini-Mental State Examination (MMSE) (0~30)

Secondary

MeasureTime frame
Montreal Cognitive Assessment (MOCA) (0~30);Modified Rankin scale (mRS) (0~6);NIHSS (National Institutes of Health Stroke Scale) (0~42);clinical dementia rating (CDR) (0~3);global deterioration scale (GDS) (1~7);white matter hyperintensity grading (minimal, moderate, severe);Scheltens' visual rating scale (hippocampal atrophy grade 0~4)

Countries

Korea, Republic of

Contacts

Public ContactYunJeong Hong

The Catholic University of Korea, Uijeongbu St. Mary’s Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 14, 2026